Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Director | April 08, 2021 | April 12, 2021 |
| Iterum Therapeutics plcITRM · Entity 72802 | Director | June 15, 2023 | June 15, 2023 |
| XERIS PHARMACEUTICALS INCXERS · Entity 134906 | See Remarks | October 05, 2021 | October 05, 2021 |
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | See Remarks | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date April 08, 2021 · Filed April 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,052 |
Reported balance
After 2021-04-08 transaction · row 1
1 source rowRow 1 · 2021-04-08 · Grant · Acquired 6,500 · Balance 9,052 F1: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer.
Iterum Therapeutics plc
Report date June 15, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 18,839 |
Reported balance
After 2023-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-15 · Exercise / conversion · Acquired 15,853 · Balance 18,839 F1: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-15 · Exercise / conversion · Disposed 15,853 · Balance 0 F1: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F3: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023. F2: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.
F2: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.
F3: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023.
XERIS PHARMACEUTICALS INC
Report date October 05, 2021 · Filed October 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,000 |
Reported balance
After 2021-10-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-10-05 · Disposition to issuer · Disposed 26,366 · Balance 180,000 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-10-05 · Disposition to issuer · Disposed 180,000 · Balance 0 F3: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.93 · Expires 2028-01-30 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-10-05 · Disposition to issuer · Disposed 30,879 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5: 25% of the options shall vest on January 16, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the sixteenth day of each month thereafter. F10: These options are early exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2028-05-14 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-10-05 · Disposition to issuer · Disposed 65,295 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: 25% of the options shall vest on May 15, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the fifteenth day of each month thereafter. F10: These options are early exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2028-10-04 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-10-05 · Disposition to issuer · Disposed 3,826 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7: 25% of the options shall vest on October 5, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the fifth day of each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2029-01-31 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-10-05 · Disposition to issuer · Disposed 32,500 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F8: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2030-08-14 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-10-05 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F9: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").
F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax.
F3: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time.
F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.
F5: 25% of the options shall vest on January 16, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the sixteenth day of each month thereafter.
F6: 25% of the options shall vest on May 15, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the fifteenth day of each month thereafter.
F7: 25% of the options shall vest on October 5, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the fifth day of each month thereafter.
F8: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
F9: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date.
F10: These options are early exercisable.
Xeris Biopharma Holdings, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,111,130 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 16,666 · Balance 1,111,130 F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.680, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.680, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neos Therapeutics, Inc.
Report date March 19, 2021 · Filed March 19, 2021
Section 16 reporting ended · disclosed 2021-03-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 1
1 source rowRow 1 · 2021-03-19 · Disposition to issuer · Disposed 23,453 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). F3: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.82 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.63 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-19 · Disposition to issuer · Disposed 14,777 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-19 · Disposition to issuer · Disposed 18,322 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-19 · Disposition to issuer · Disposed 22,756 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-19 · Disposition to issuer · Disposed 46,907 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time").
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement).
F3: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock.
F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:54 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,666 | $9.41 | $156,792.06 |
DisclosureSEC source: 0001867096-26-000084 · wk-form4_1790974451.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,111,130 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.680, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 22:21 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,666 | $8.49 | $141,434.34 |
DisclosureSEC source: 0001652410-26-000018 · wk-form4_1788301263.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,127,796 F1 · kind: The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 21:16 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,666 | $8.01 | $133,552.99 |
DisclosureSEC source: 0001652410-26-000016 · wk-form4_1785878178.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,144,462 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.870 to $8.140, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,666 | $8.03 | $133,859.65 |
DisclosureSEC source: 0001652410-26-000014 · wk-form4_1783024734.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,161,128 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.92 to $8.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 1,288 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:05 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,667 | $6.06 | $100,982.02 |
DisclosureSEC source: 0001652410-26-000012 · wk-form4_1780437901.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,176,506 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.980 to $6.180, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 1, 2026 21:50 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,667 | $6.23 | $103,805.41 |
DisclosureSEC source: 0001652410-26-000010 · wk-form4_1777672230.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,193,173 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.100 to $6.320, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:45 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,667 | $5.99 | $99,858.66 |
DisclosureSEC source: 0001652410-26-000008 · wk-form4_1775252722.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,209,840 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.890 to $6.085, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:28 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 100 | $7.06 | $706.00 |
DisclosureSEC source: 0001652410-26-000006 · wk-form4_1772663325.xml · nonDerivative · entry 2 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,226,507 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:28 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,567 | $6.24 | $103,379.74 |
DisclosureSEC source: 0001652410-26-000006 · wk-form4_1772663325.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,226,607 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.920 to $6.910, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 23:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,667 | $7.45 | $124,147.48 |
DisclosureSEC source: 0001652410-26-000004 · wk-form4_1770073868.xml · nonDerivative · entry 5 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,243,174 F3 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.590, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 24,266 | $7.36 | $178,597.76 |
DisclosureSEC source: 0001652410-26-000004 · wk-form4_1770073868.xml · nonDerivative · entry 4 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,259,841 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 46,914 | $7.36 | $345,287.04 |
DisclosureSEC source: 0001652410-26-000004 · wk-form4_1770073868.xml · nonDerivative · entry 3 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,284,107 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 98,375 | $7.36 | $724,040.00 |
DisclosureSEC source: 0001652410-26-000004 · wk-form4_1770073868.xml · nonDerivative · entry 2 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,331,021 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 23:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 162,162 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001652410-26-000004 · wk-form4_1770073868.xml · derivative · entry 6 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,162 Underlying: Common Stock · 162,162 shares Expires 2036-01-30 F5 · derivative.exercise_date: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 23:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 121,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001652410-26-000004 · wk-form4_1770073868.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429,396 F1 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:01 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,667 | $7.43 | $123,775.81 |
DisclosureSEC source: 0001652410-26-000002 · wk-form4_1767654116.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,308,103 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.280 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 2,627 shares acquired on June 30, 2025 and 1,967 shares acquired on December 31, 2025 under the issuer's 2018 Employee Stock Purchase Plan, as amended. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 22:14 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,667 | $7.01 | $116,780.67 |
DisclosureSEC source: 0001652410-25-000005 · wk-form4_1764713658.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,320,176 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.930 to $7.120, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 23:59 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 16,667 | $7.40 | $123,295.80 |
DisclosureSEC source: 0001652410-25-000003 · wk-form4_1763078372.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,336,843 F1 · kind: The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.290 to $7.750, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 21:31 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 40,000 | $5.43 | $217,244.00 |
DisclosureSEC source: 0001867096-25-000047 · wk-form4_1742592654.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,353,510 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.380 to $5.475, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:39 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Appreciation Right · Derivative | 300,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001867096-25-000025 · wk-form4_1738629587.xml · derivative · entry 4 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-03-02 F3 · derivative.exercise_date: This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date. F4 · derivative.underlying: Upon exercise, the stock appreciation right will be settled in cash. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:39 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 185,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-25-000025 · wk-form4_1738629587.xml · nonDerivative · entry 3 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,393,510 F2 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:39 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 98,375 | $3.56 | $350,215.00 |
DisclosureSEC source: 0001867096-25-000025 · wk-form4_1738629587.xml · nonDerivative · entry 2 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,208,510 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:39 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 45,909 | $3.56 | $163,436.04 |
DisclosureSEC source: 0001867096-25-000025 · wk-form4_1738629587.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,306,885 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 32,039 | $3.61 | $115,660.79 |
DisclosureSEC source: 0001867096-25-000011 · wk-form4_1736286048.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,352,794 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025. F2 · balance_after: Includes 4,031 shares acquired on December 31, 2024 under the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, as amended. Read SEC document |
| January 31, 2024 Filed Jan 31, 2024 22:04 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-24-000015 · wk-form4_1706738674.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,554,968 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 7,210 shares that were purchased on June 30, 2023 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2024 Filed Aug 9, 2024 20:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 45,909 | $2.46 | $112,936.14 |
DisclosureSEC source: 0001867096-24-000170 · wk-form4_1723234030.xml · nonDerivative · entry 8 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,380,802 F1 · date: This transaction is being reported late due to administrative oversight. F10 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024. Read SEC document |
| January 29, 2024 Filed Aug 9, 2024 20:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 19,675 | $2.66 | $52,335.50 |
DisclosureSEC source: 0001867096-24-000170 · wk-form4_1723234030.xml · nonDerivative · entry 7 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,426,711 F1 · date: This transaction is being reported late due to administrative oversight. F9 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024. Read SEC document |
| January 03, 2024 Filed Aug 9, 2024 20:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 33,488 | $2.24 | $75,013.12 |
DisclosureSEC source: 0001867096-24-000170 · wk-form4_1723234030.xml · nonDerivative · entry 6 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,446,386 F1 · date: This transaction is being reported late due to administrative oversight. F8 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024. Read SEC document |
| June 15, 2023 Filed Jun 15, 2023 21:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 15,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037406 · doc4.xml · derivative · entry 2 Hecht Beth · CIK 0001652410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,853 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F3 · derivative.exercise_date: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023. F3 · derivative.expiration_date: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023. F2 · derivative.underlying_shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split. Read SEC document |
| June 15, 2023 Filed Jun 15, 2023 21:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 15,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037406 · doc4.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · balance_after: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split. Read SEC document |
| January 31, 2023 Filed Feb 1, 2023 21:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-23-000020 · wf-form4_167528592477189.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,758 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 5,039 shares that were purchased on June 30, 2022 and 5,898 shares that were purchased on December 31, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2023 Filed Aug 9, 2024 20:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 5,784 | $1.24 | $7,172.16 |
DisclosureSEC source: 0001867096-24-000170 · wk-form4_1723234030.xml · nonDerivative · entry 5 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,479,874 F1 · date: This transaction is being reported late due to administrative oversight. F7 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023. Read SEC document |
| January 29, 2023 Filed Aug 9, 2024 20:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 21,177 | $1.26 | $26,683.02 |
DisclosureSEC source: 0001867096-24-000170 · wk-form4_1723234030.xml · nonDerivative · entry 4 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,485,658 F1 · date: This transaction is being reported late due to administrative oversight. F6 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023. Read SEC document |
| January 03, 2023 Filed Aug 9, 2024 20:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 33,488 | $1.12 | $37,506.56 |
DisclosureSEC source: 0001867096-24-000170 · wk-form4_1723234030.xml · nonDerivative · entry 3 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,506,835 F1 · date: This transaction is being reported late due to administrative oversight. F5 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 36,798 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039311 · doc4.xml · derivative · entry 2 Hecht Beth · CIK 0001652410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · derivative.exercise_date: On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022. F2 · derivative.expiration_date: On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 36,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039311 · doc4.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:02 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Share Units · Derivative | 237,795 | $0.01 | $2,377.95 |
DisclosureSEC source: 0001209191-22-037950 · doc4.xml · derivative · entry 1 Hecht Beth · CIK 0001652410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,795 Underlying: Ordinary Shares · 237,795 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 15, 2023. F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 15, 2023. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 23:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 7,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-020618 · doc4.xml · derivative · entry 2 Hecht Beth · CIK 0001652410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,642 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · derivative.exercise_date: On March 18, 2021, the reporting person was granted an award of 7,642 RSUs, which vested on March 18, 2022. F2 · derivative.expiration_date: On March 18, 2021, the reporting person was granted an award of 7,642 RSUs, which vested on March 18, 2022. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 23:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 7,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-020618 · doc4.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| January 31, 2022 Filed Aug 9, 2024 20:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 4,448 | $2.11 | $9,385.28 |
DisclosureSEC source: 0001867096-24-000170 · wk-form4_1723234030.xml · nonDerivative · entry 2 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,540,323 F1 · date: This transaction is being reported late due to administrative oversight. F4 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022. Read SEC document |
| January 29, 2022 Filed Aug 9, 2024 20:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 14,037 | $2.11 | $29,618.07 |
DisclosureSEC source: 0001867096-24-000170 · wk-form4_1723234030.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,544,771 F1 · date: This transaction is being reported late due to administrative oversight. F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022. F3 · balance_after: These shares include 3,840 shares that were purchased on June 30, 2024 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 23:16 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-22-000009 · wf-form4_164142458670226.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,821 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 3,000 shares that were purchased on June 30, 2021 and 2,455 shares that were purchased on December 31, 2021 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:34 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039248 · doc4.xml · derivative · entry 7 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2030-08-14 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F9 · derivative.exercise_date: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:34 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,500 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039248 · doc4.xml · derivative · entry 6 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2029-01-31 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F8 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:34 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,826 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-039248 · doc4.xml · derivative · entry 5 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,826 shares Expires 2028-10-04 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7 · derivative.exercise_date: 25% of the options shall vest on October 5, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the fifth day of each month thereafter. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:34 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 65,295 | Not disclosed Strike: $12.50 | Not disclosed |
DisclosureSEC source: 0000899243-21-039248 · doc4.xml · derivative · entry 4 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,295 shares Expires 2028-05-14 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of the options shall vest on May 15, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the fifteenth day of each month thereafter. F10 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:34 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,879 | Not disclosed Strike: $5.93 | Not disclosed |
DisclosureSEC source: 0000899243-21-039248 · doc4.xml · derivative · entry 3 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,879 shares Expires 2028-01-30 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: 25% of the options shall vest on January 16, 2019, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the sixteenth day of each month thereafter. F10 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:34 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerCommon Stock | 180,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039248 · doc4.xml · nonDerivative · entry 2 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:34 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerCommon Stock | 26,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039248 · doc4.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:37 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039317 · doc4.xml · derivative · entry 7 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-08-14 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F9 · derivative.exercise_date: 50% of these options vested on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.